I'll take 140..same price Onxx should have got.
Hasn't ALXN already priced itself out of the market with a market cap of $21B?
99% of biotech buyouts come to companies with market caps between $500M and $5B.
Who can afford to spend $25B for a single orphan drug? (Even with potential multiple indications.)
there will be no take out... I have been saying that for months too bad you did not listen
not such a bad thing. quick money is nice but this is going up slowly but surely. roche wanted ilmn and didnt get that. but that has since gone way past their offer.